Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

norethindrone and ethinyl estradiol and ferrous fumarate

×

Overview

What is NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE?

Norethindrone and ethinyl estradiol tablets (chewable) 0.8 mg/0.025 mg and ferrous fumarate tablets (chewable) 75 mg provides an oral contraceptive regimen consisting of 24 tablets that contain the active ingredients specified below, followed by four non-hormonal placebo tablets:

Each dark yellow tablet also contains the following inactive ingredients: lactose monohydrate, anhydrous lactose, sodium starch glycolate type A (potato), D&C Yellow No. 10 Aluminum Lake, povidone K-30, calcium phosphate (dibasic dehydrate), colloidal silicon dioxide, maltodextrin, sucralose, spearmint flavor and magnesium stearate.

Each brown, round tablet contains ferrous fumarate, microcrystalline cellulose, lactose monohydrate, povidone K-90, croscarmellose sodium, colloidal silicon dioxide, sucralose, spearmint flavor, magnesium stearate. The ferrous fumarate tablets (chewable) do not serve any therapeutic purpose. Ferrous fumarate tablets (chewable) are not USP for dissolution and assay.

The molecular formula of ethinyl estradiol is CHO and the chemical structure is:

The chemical name of ethinyl estradiol is [19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17α)-]

The molecular formula of norethindrone is CHO and the chemical structure is:

The chemical name of norethindrone is [17-Hydroxy-19-nor-17α-pregn-4-en-20-yn-3-one]



What does NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE look like?



What are the available doses of NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE?

Norethindrone and ethinyl estradiol tablets (chewable) and ferrous fumarate tablets (chewable) are available in blister packs.

Each blister pack (28 tablets) contains in the following order:

What should I talk to my health care provider before I take NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE?

How should I use NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE?

To achieve maximum contraceptive effectiveness, norethindrone and ethinyl estradiol tablets (chewable) and ferrous fumarate tablets (chewable) must be taken exactly as directed. Chew and swallow one tablet without water at the same time every day. Tablets must be taken in the order directed on the blister pack. Tablets should not be skipped or taken at intervals exceeding 24 hours. For patient instructions for missed pills, see . Norethindrone and ethinyl estradiol tablets (chewable) and ferrous fumarate tablets (chewable) may be administered without regard to meals .


What interacts with NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE?

Sorry No Records found


What are the warnings of NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE?

Sorry No Records found


What are the precautions of NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE?

Sorry No Records found


What are the side effects of NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE?

Sorry No records found


What should I look out for while using NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE?

•

4

•

4

•

4

•

4

•

4

•

4

(1)

(2)

(4)

®

(5)

(6)

(7)

(8)


What might happen if I take too much NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE?

There have been no reports of serious ill effects from overdose of oral contraceptives including ingestion by children. Overdosage may cause nausea, and withdrawal bleeding may occur in females.


How should I store and handle NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE?

Store at 20° to 25°C (68° to 77°F)Protect from moisture.Store at 20° to 25°C (68° to 77°F)Protect from moisture.Haloperidol tablets, USP for oral administration are available as:0.5 mg:NDC 0781-1391-01 bottles of 100NDC 0781-1391-10 bottles of 1000NDC 0781-1391-13 unit dose packages of 1001 mg:NDC 0781-1392-01 bottles of 100NDC 0781-1392-10 bottles of 1000NDC 0781-1392-13 unit dose packages of 1002 mg:NDC 0781-1393-01 bottles of 100NDC 0781-1393-10 bottles of 1000NDC 0781-1393-13 unit dose packages of 1005 mg:NDC 0781-1396-01 bottles of 100NDC 0781-1396-10 bottles of 1000NDC 0781-1396-13 unit dose packages of 10010 mg:NDC 0781-1397-01 bottles of 100NDC 0781-1397-10 bottles of 1000NDC 0781-1397-13 unit dose packages of 10020 mg:NDC 0781-1398-01 bottles of 100NDC 0781-1398-10 bottles of 1000Haloperidol tablets, USP for oral administration are available as:0.5 mg:NDC 0781-1391-01 bottles of 100NDC 0781-1391-10 bottles of 1000NDC 0781-1391-13 unit dose packages of 1001 mg:NDC 0781-1392-01 bottles of 100NDC 0781-1392-10 bottles of 1000NDC 0781-1392-13 unit dose packages of 1002 mg:NDC 0781-1393-01 bottles of 100NDC 0781-1393-10 bottles of 1000NDC 0781-1393-13 unit dose packages of 1005 mg:NDC 0781-1396-01 bottles of 100NDC 0781-1396-10 bottles of 1000NDC 0781-1396-13 unit dose packages of 10010 mg:NDC 0781-1397-01 bottles of 100NDC 0781-1397-10 bottles of 1000NDC 0781-1397-13 unit dose packages of 10020 mg:NDC 0781-1398-01 bottles of 100NDC 0781-1398-10 bottles of 1000Haloperidol tablets, USP for oral administration are available as:0.5 mg:NDC 0781-1391-01 bottles of 100NDC 0781-1391-10 bottles of 1000NDC 0781-1391-13 unit dose packages of 1001 mg:NDC 0781-1392-01 bottles of 100NDC 0781-1392-10 bottles of 1000NDC 0781-1392-13 unit dose packages of 1002 mg:NDC 0781-1393-01 bottles of 100NDC 0781-1393-10 bottles of 1000NDC 0781-1393-13 unit dose packages of 1005 mg:NDC 0781-1396-01 bottles of 100NDC 0781-1396-10 bottles of 1000NDC 0781-1396-13 unit dose packages of 10010 mg:NDC 0781-1397-01 bottles of 100NDC 0781-1397-10 bottles of 1000NDC 0781-1397-13 unit dose packages of 10020 mg:NDC 0781-1398-01 bottles of 100NDC 0781-1398-10 bottles of 1000Haloperidol tablets, USP for oral administration are available as:0.5 mg:NDC 0781-1391-01 bottles of 100NDC 0781-1391-10 bottles of 1000NDC 0781-1391-13 unit dose packages of 1001 mg:NDC 0781-1392-01 bottles of 100NDC 0781-1392-10 bottles of 1000NDC 0781-1392-13 unit dose packages of 1002 mg:NDC 0781-1393-01 bottles of 100NDC 0781-1393-10 bottles of 1000NDC 0781-1393-13 unit dose packages of 1005 mg:NDC 0781-1396-01 bottles of 100NDC 0781-1396-10 bottles of 1000NDC 0781-1396-13 unit dose packages of 10010 mg:NDC 0781-1397-01 bottles of 100NDC 0781-1397-10 bottles of 1000NDC 0781-1397-13 unit dose packages of 10020 mg:NDC 0781-1398-01 bottles of 100NDC 0781-1398-10 bottles of 1000Haloperidol tablets, USP for oral administration are available as:0.5 mg:NDC 0781-1391-01 bottles of 100NDC 0781-1391-10 bottles of 1000NDC 0781-1391-13 unit dose packages of 1001 mg:NDC 0781-1392-01 bottles of 100NDC 0781-1392-10 bottles of 1000NDC 0781-1392-13 unit dose packages of 1002 mg:NDC 0781-1393-01 bottles of 100NDC 0781-1393-10 bottles of 1000NDC 0781-1393-13 unit dose packages of 1005 mg:NDC 0781-1396-01 bottles of 100NDC 0781-1396-10 bottles of 1000NDC 0781-1396-13 unit dose packages of 10010 mg:NDC 0781-1397-01 bottles of 100NDC 0781-1397-10 bottles of 1000NDC 0781-1397-13 unit dose packages of 10020 mg:NDC 0781-1398-01 bottles of 100NDC 0781-1398-10 bottles of 1000Haloperidol tablets, USP for oral administration are available as:0.5 mg:NDC 0781-1391-01 bottles of 100NDC 0781-1391-10 bottles of 1000NDC 0781-1391-13 unit dose packages of 1001 mg:NDC 0781-1392-01 bottles of 100NDC 0781-1392-10 bottles of 1000NDC 0781-1392-13 unit dose packages of 1002 mg:NDC 0781-1393-01 bottles of 100NDC 0781-1393-10 bottles of 1000NDC 0781-1393-13 unit dose packages of 1005 mg:NDC 0781-1396-01 bottles of 100NDC 0781-1396-10 bottles of 1000NDC 0781-1396-13 unit dose packages of 10010 mg:NDC 0781-1397-01 bottles of 100NDC 0781-1397-10 bottles of 1000NDC 0781-1397-13 unit dose packages of 10020 mg:NDC 0781-1398-01 bottles of 100NDC 0781-1398-10 bottles of 1000Haloperidol tablets, USP for oral administration are available as:0.5 mg:NDC 0781-1391-01 bottles of 100NDC 0781-1391-10 bottles of 1000NDC 0781-1391-13 unit dose packages of 1001 mg:NDC 0781-1392-01 bottles of 100NDC 0781-1392-10 bottles of 1000NDC 0781-1392-13 unit dose packages of 1002 mg:NDC 0781-1393-01 bottles of 100NDC 0781-1393-10 bottles of 1000NDC 0781-1393-13 unit dose packages of 1005 mg:NDC 0781-1396-01 bottles of 100NDC 0781-1396-10 bottles of 1000NDC 0781-1396-13 unit dose packages of 10010 mg:NDC 0781-1397-01 bottles of 100NDC 0781-1397-10 bottles of 1000NDC 0781-1397-13 unit dose packages of 10020 mg:NDC 0781-1398-01 bottles of 100NDC 0781-1398-10 bottles of 1000Haloperidol tablets, USP for oral administration are available as:0.5 mg:NDC 0781-1391-01 bottles of 100NDC 0781-1391-10 bottles of 1000NDC 0781-1391-13 unit dose packages of 1001 mg:NDC 0781-1392-01 bottles of 100NDC 0781-1392-10 bottles of 1000NDC 0781-1392-13 unit dose packages of 1002 mg:NDC 0781-1393-01 bottles of 100NDC 0781-1393-10 bottles of 1000NDC 0781-1393-13 unit dose packages of 1005 mg:NDC 0781-1396-01 bottles of 100NDC 0781-1396-10 bottles of 1000NDC 0781-1396-13 unit dose packages of 10010 mg:NDC 0781-1397-01 bottles of 100NDC 0781-1397-10 bottles of 1000NDC 0781-1397-13 unit dose packages of 10020 mg:NDC 0781-1398-01 bottles of 100NDC 0781-1398-10 bottles of 1000Haloperidol tablets, USP for oral administration are available as:0.5 mg:NDC 0781-1391-01 bottles of 100NDC 0781-1391-10 bottles of 1000NDC 0781-1391-13 unit dose packages of 1001 mg:NDC 0781-1392-01 bottles of 100NDC 0781-1392-10 bottles of 1000NDC 0781-1392-13 unit dose packages of 1002 mg:NDC 0781-1393-01 bottles of 100NDC 0781-1393-10 bottles of 1000NDC 0781-1393-13 unit dose packages of 1005 mg:NDC 0781-1396-01 bottles of 100NDC 0781-1396-10 bottles of 1000NDC 0781-1396-13 unit dose packages of 10010 mg:NDC 0781-1397-01 bottles of 100NDC 0781-1397-10 bottles of 1000NDC 0781-1397-13 unit dose packages of 10020 mg:NDC 0781-1398-01 bottles of 100NDC 0781-1398-10 bottles of 1000Haloperidol tablets, USP for oral administration are available as:0.5 mg:NDC 0781-1391-01 bottles of 100NDC 0781-1391-10 bottles of 1000NDC 0781-1391-13 unit dose packages of 1001 mg:NDC 0781-1392-01 bottles of 100NDC 0781-1392-10 bottles of 1000NDC 0781-1392-13 unit dose packages of 1002 mg:NDC 0781-1393-01 bottles of 100NDC 0781-1393-10 bottles of 1000NDC 0781-1393-13 unit dose packages of 1005 mg:NDC 0781-1396-01 bottles of 100NDC 0781-1396-10 bottles of 1000NDC 0781-1396-13 unit dose packages of 10010 mg:NDC 0781-1397-01 bottles of 100NDC 0781-1397-10 bottles of 1000NDC 0781-1397-13 unit dose packages of 10020 mg:NDC 0781-1398-01 bottles of 100NDC 0781-1398-10 bottles of 1000Haloperidol tablets, USP for oral administration are available as:0.5 mg:NDC 0781-1391-01 bottles of 100NDC 0781-1391-10 bottles of 1000NDC 0781-1391-13 unit dose packages of 1001 mg:NDC 0781-1392-01 bottles of 100NDC 0781-1392-10 bottles of 1000NDC 0781-1392-13 unit dose packages of 1002 mg:NDC 0781-1393-01 bottles of 100NDC 0781-1393-10 bottles of 1000NDC 0781-1393-13 unit dose packages of 1005 mg:NDC 0781-1396-01 bottles of 100NDC 0781-1396-10 bottles of 1000NDC 0781-1396-13 unit dose packages of 10010 mg:NDC 0781-1397-01 bottles of 100NDC 0781-1397-10 bottles of 1000NDC 0781-1397-13 unit dose packages of 10020 mg:NDC 0781-1398-01 bottles of 100NDC 0781-1398-10 bottles of 1000Haloperidol tablets, USP for oral administration are available as:0.5 mg:NDC 0781-1391-01 bottles of 100NDC 0781-1391-10 bottles of 1000NDC 0781-1391-13 unit dose packages of 1001 mg:NDC 0781-1392-01 bottles of 100NDC 0781-1392-10 bottles of 1000NDC 0781-1392-13 unit dose packages of 1002 mg:NDC 0781-1393-01 bottles of 100NDC 0781-1393-10 bottles of 1000NDC 0781-1393-13 unit dose packages of 1005 mg:NDC 0781-1396-01 bottles of 100NDC 0781-1396-10 bottles of 1000NDC 0781-1396-13 unit dose packages of 10010 mg:NDC 0781-1397-01 bottles of 100NDC 0781-1397-10 bottles of 1000NDC 0781-1397-13 unit dose packages of 10020 mg:NDC 0781-1398-01 bottles of 100NDC 0781-1398-10 bottles of 1000Haloperidol tablets, USP for oral administration are available as:0.5 mg:NDC 0781-1391-01 bottles of 100NDC 0781-1391-10 bottles of 1000NDC 0781-1391-13 unit dose packages of 1001 mg:NDC 0781-1392-01 bottles of 100NDC 0781-1392-10 bottles of 1000NDC 0781-1392-13 unit dose packages of 1002 mg:NDC 0781-1393-01 bottles of 100NDC 0781-1393-10 bottles of 1000NDC 0781-1393-13 unit dose packages of 1005 mg:NDC 0781-1396-01 bottles of 100NDC 0781-1396-10 bottles of 1000NDC 0781-1396-13 unit dose packages of 10010 mg:NDC 0781-1397-01 bottles of 100NDC 0781-1397-10 bottles of 1000NDC 0781-1397-13 unit dose packages of 10020 mg:NDC 0781-1398-01 bottles of 100NDC 0781-1398-10 bottles of 1000Haloperidol tablets, USP for oral administration are available as:0.5 mg:NDC 0781-1391-01 bottles of 100NDC 0781-1391-10 bottles of 1000NDC 0781-1391-13 unit dose packages of 1001 mg:NDC 0781-1392-01 bottles of 100NDC 0781-1392-10 bottles of 1000NDC 0781-1392-13 unit dose packages of 1002 mg:NDC 0781-1393-01 bottles of 100NDC 0781-1393-10 bottles of 1000NDC 0781-1393-13 unit dose packages of 1005 mg:NDC 0781-1396-01 bottles of 100NDC 0781-1396-10 bottles of 1000NDC 0781-1396-13 unit dose packages of 10010 mg:NDC 0781-1397-01 bottles of 100NDC 0781-1397-10 bottles of 1000NDC 0781-1397-13 unit dose packages of 10020 mg:NDC 0781-1398-01 bottles of 100NDC 0781-1398-10 bottles of 1000Haloperidol tablets, USP for oral administration are available as:0.5 mg:NDC 0781-1391-01 bottles of 100NDC 0781-1391-10 bottles of 1000NDC 0781-1391-13 unit dose packages of 1001 mg:NDC 0781-1392-01 bottles of 100NDC 0781-1392-10 bottles of 1000NDC 0781-1392-13 unit dose packages of 1002 mg:NDC 0781-1393-01 bottles of 100NDC 0781-1393-10 bottles of 1000NDC 0781-1393-13 unit dose packages of 1005 mg:NDC 0781-1396-01 bottles of 100NDC 0781-1396-10 bottles of 1000NDC 0781-1396-13 unit dose packages of 10010 mg:NDC 0781-1397-01 bottles of 100NDC 0781-1397-10 bottles of 1000NDC 0781-1397-13 unit dose packages of 10020 mg:NDC 0781-1398-01 bottles of 100NDC 0781-1398-10 bottles of 1000Haloperidol tablets, USP for oral administration are available as:0.5 mg:NDC 0781-1391-01 bottles of 100NDC 0781-1391-10 bottles of 1000NDC 0781-1391-13 unit dose packages of 1001 mg:NDC 0781-1392-01 bottles of 100NDC 0781-1392-10 bottles of 1000NDC 0781-1392-13 unit dose packages of 1002 mg:NDC 0781-1393-01 bottles of 100NDC 0781-1393-10 bottles of 1000NDC 0781-1393-13 unit dose packages of 1005 mg:NDC 0781-1396-01 bottles of 100NDC 0781-1396-10 bottles of 1000NDC 0781-1396-13 unit dose packages of 10010 mg:NDC 0781-1397-01 bottles of 100NDC 0781-1397-10 bottles of 1000NDC 0781-1397-13 unit dose packages of 10020 mg:NDC 0781-1398-01 bottles of 100NDC 0781-1398-10 bottles of 1000Haloperidol tablets, USP for oral administration are available as:0.5 mg:NDC 0781-1391-01 bottles of 100NDC 0781-1391-10 bottles of 1000NDC 0781-1391-13 unit dose packages of 1001 mg:NDC 0781-1392-01 bottles of 100NDC 0781-1392-10 bottles of 1000NDC 0781-1392-13 unit dose packages of 1002 mg:NDC 0781-1393-01 bottles of 100NDC 0781-1393-10 bottles of 1000NDC 0781-1393-13 unit dose packages of 1005 mg:NDC 0781-1396-01 bottles of 100NDC 0781-1396-10 bottles of 1000NDC 0781-1396-13 unit dose packages of 10010 mg:NDC 0781-1397-01 bottles of 100NDC 0781-1397-10 bottles of 1000NDC 0781-1397-13 unit dose packages of 10020 mg:NDC 0781-1398-01 bottles of 100NDC 0781-1398-10 bottles of 1000Haloperidol tablets, USP for oral administration are available as:0.5 mg:NDC 0781-1391-01 bottles of 100NDC 0781-1391-10 bottles of 1000NDC 0781-1391-13 unit dose packages of 1001 mg:NDC 0781-1392-01 bottles of 100NDC 0781-1392-10 bottles of 1000NDC 0781-1392-13 unit dose packages of 1002 mg:NDC 0781-1393-01 bottles of 100NDC 0781-1393-10 bottles of 1000NDC 0781-1393-13 unit dose packages of 1005 mg:NDC 0781-1396-01 bottles of 100NDC 0781-1396-10 bottles of 1000NDC 0781-1396-13 unit dose packages of 10010 mg:NDC 0781-1397-01 bottles of 100NDC 0781-1397-10 bottles of 1000NDC 0781-1397-13 unit dose packages of 10020 mg:NDC 0781-1398-01 bottles of 100NDC 0781-1398-10 bottles of 1000Haloperidol tablets, USP for oral administration are available as:0.5 mg:NDC 0781-1391-01 bottles of 100NDC 0781-1391-10 bottles of 1000NDC 0781-1391-13 unit dose packages of 1001 mg:NDC 0781-1392-01 bottles of 100NDC 0781-1392-10 bottles of 1000NDC 0781-1392-13 unit dose packages of 1002 mg:NDC 0781-1393-01 bottles of 100NDC 0781-1393-10 bottles of 1000NDC 0781-1393-13 unit dose packages of 1005 mg:NDC 0781-1396-01 bottles of 100NDC 0781-1396-10 bottles of 1000NDC 0781-1396-13 unit dose packages of 10010 mg:NDC 0781-1397-01 bottles of 100NDC 0781-1397-10 bottles of 1000NDC 0781-1397-13 unit dose packages of 10020 mg:NDC 0781-1398-01 bottles of 100NDC 0781-1398-10 bottles of 1000Haloperidol tablets, USP for oral administration are available as:0.5 mg:NDC 0781-1391-01 bottles of 100NDC 0781-1391-10 bottles of 1000NDC 0781-1391-13 unit dose packages of 1001 mg:NDC 0781-1392-01 bottles of 100NDC 0781-1392-10 bottles of 1000NDC 0781-1392-13 unit dose packages of 1002 mg:NDC 0781-1393-01 bottles of 100NDC 0781-1393-10 bottles of 1000NDC 0781-1393-13 unit dose packages of 1005 mg:NDC 0781-1396-01 bottles of 100NDC 0781-1396-10 bottles of 1000NDC 0781-1396-13 unit dose packages of 10010 mg:NDC 0781-1397-01 bottles of 100NDC 0781-1397-10 bottles of 1000NDC 0781-1397-13 unit dose packages of 10020 mg:NDC 0781-1398-01 bottles of 100NDC 0781-1398-10 bottles of 1000Haloperidol tablets, USP for oral administration are available as:0.5 mg:NDC 0781-1391-01 bottles of 100NDC 0781-1391-10 bottles of 1000NDC 0781-1391-13 unit dose packages of 1001 mg:NDC 0781-1392-01 bottles of 100NDC 0781-1392-10 bottles of 1000NDC 0781-1392-13 unit dose packages of 1002 mg:NDC 0781-1393-01 bottles of 100NDC 0781-1393-10 bottles of 1000NDC 0781-1393-13 unit dose packages of 1005 mg:NDC 0781-1396-01 bottles of 100NDC 0781-1396-10 bottles of 1000NDC 0781-1396-13 unit dose packages of 10010 mg:NDC 0781-1397-01 bottles of 100NDC 0781-1397-10 bottles of 1000NDC 0781-1397-13 unit dose packages of 10020 mg:NDC 0781-1398-01 bottles of 100NDC 0781-1398-10 bottles of 1000Haloperidol tablets, USP for oral administration are available as:0.5 mg:NDC 0781-1391-01 bottles of 100NDC 0781-1391-10 bottles of 1000NDC 0781-1391-13 unit dose packages of 1001 mg:NDC 0781-1392-01 bottles of 100NDC 0781-1392-10 bottles of 1000NDC 0781-1392-13 unit dose packages of 1002 mg:NDC 0781-1393-01 bottles of 100NDC 0781-1393-10 bottles of 1000NDC 0781-1393-13 unit dose packages of 1005 mg:NDC 0781-1396-01 bottles of 100NDC 0781-1396-10 bottles of 1000NDC 0781-1396-13 unit dose packages of 10010 mg:NDC 0781-1397-01 bottles of 100NDC 0781-1397-10 bottles of 1000NDC 0781-1397-13 unit dose packages of 10020 mg:NDC 0781-1398-01 bottles of 100NDC 0781-1398-10 bottles of 1000Haloperidol tablets, USP for oral administration are available as:0.5 mg:NDC 0781-1391-01 bottles of 100NDC 0781-1391-10 bottles of 1000NDC 0781-1391-13 unit dose packages of 1001 mg:NDC 0781-1392-01 bottles of 100NDC 0781-1392-10 bottles of 1000NDC 0781-1392-13 unit dose packages of 1002 mg:NDC 0781-1393-01 bottles of 100NDC 0781-1393-10 bottles of 1000NDC 0781-1393-13 unit dose packages of 1005 mg:NDC 0781-1396-01 bottles of 100NDC 0781-1396-10 bottles of 1000NDC 0781-1396-13 unit dose packages of 10010 mg:NDC 0781-1397-01 bottles of 100NDC 0781-1397-10 bottles of 1000NDC 0781-1397-13 unit dose packages of 10020 mg:NDC 0781-1398-01 bottles of 100NDC 0781-1398-10 bottles of 1000Haloperidol tablets, USP for oral administration are available as:0.5 mg:NDC 0781-1391-01 bottles of 100NDC 0781-1391-10 bottles of 1000NDC 0781-1391-13 unit dose packages of 1001 mg:NDC 0781-1392-01 bottles of 100NDC 0781-1392-10 bottles of 1000NDC 0781-1392-13 unit dose packages of 1002 mg:NDC 0781-1393-01 bottles of 100NDC 0781-1393-10 bottles of 1000NDC 0781-1393-13 unit dose packages of 1005 mg:NDC 0781-1396-01 bottles of 100NDC 0781-1396-10 bottles of 1000NDC 0781-1396-13 unit dose packages of 10010 mg:NDC 0781-1397-01 bottles of 100NDC 0781-1397-10 bottles of 1000NDC 0781-1397-13 unit dose packages of 10020 mg:NDC 0781-1398-01 bottles of 100NDC 0781-1398-10 bottles of 1000


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

COCs lower the risk of becoming pregnant primarily by suppressing ovulation. Other possible mechanisms may include cervical mucus changes that inhibit sperm penetration and endometrial changes that reduce the likelihood of implantation.

Non-Clinical Toxicology
•

4

•

4

•

4

•

4

•

4

•

4

Clinically meaningful drug interactions have occurred with concomitant medications and include, but are not limited to the following:

Agents Highly Bound to Plasma Protein:

Carbamazepine is not highly bound to plasma proteins; therefore, administration of Carbatrol to a patient taking another drug that is highly protein bound should not cause increased free concentrations of the other drug.

Agents that Inhibit Cytochrome P450 Isoenzymes and/or Epoxide Hydrolase:

Carbamazepine is metabolized mainly by cytochrome P450 (CYP) 3A4 to the active carbamazepine 10,11-epoxide, which is further metabolized to the trans-diol by epoxide hydrolase. Therefore, the potential exists for interaction between carbamazepine and any agent that inhibits CYP3A4 and/or epoxide hydrolase. Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of Carbatrol are the following:

Acetazolamide, azole antifungals, cimetidine, clarithromycin(), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(), verapamil, zileuton.

Array

Thus, if a patient has been titrated to a stable dosage of Carbatrol, and then begins a course of treatment with one of these CYP3A4 or epoxide hydrolase inhibitors, it is reasonable to expect that a dose reduction for Carbatrol may be necessary.

Agents that Induce Cytochrome P450 Isoenzymes:

Carbamazepine is metabolized by CYP3A4. Therefore, the potential exists for interaction between carbamazepine and any agent that induces CYP3A4. Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of Carbatrol are the following:

Cisplatin, doxorubicin HCL, felbamate, rifampin, phenobarbital, phenytoin(), primidone, methsuximide, and theophylline

Array

Thus, if a patient has been titrated to a stable dosage on Carbatrol, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for Carbatrol may be necessary.

Agents with Decreased Levels in the Presence of Carbamazepine due to Induction of Cytochrome P450 Enzymes:

Carbamazepine is known to induce CYP1A2 and CYP3A4. Therefore, the potential exists for interaction between carbamazepine and any agent metabolized by one (or more) of these enzymes. Agents that have been found, or are expected to have decreased plasma levels in the presence of Carbatrol due to induction of CYP enzymes are the following:

Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral and other hormonal contraceptives(), oxcarbazepine, phenytoin(), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, trazodone(), valproate, warfarin(), ziprasidone, and zonisamide.





Array

Array

Array

Array

Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of treatment with Carbatrol, it is reasonable to expect that a dose increase for the concomitant agent may be necessary.

Agents with Increased Levels in the Presence of Carbamazepine:

Carbatrol increases the plasma levels of the following agents:

Clomipramine HCl, phenytoin(), and primidone

Array

Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with Carbatrol, it is reasonable to expect that a dose decrease for the concomitant agent may be necessary.

Pharmacological/Pharmacodynamic Interactions with Carbamazepine:

Coadministration of Carbatrolwith delavirdine may lead to loss of virologic response and possible resistance to delavirdine or to the class of non-nucleoside reverse transcriptase inhibitors (see ).

Concomitant administration of carbamazepine and lithium may increase the risk of neurotoxic side effects.

Given the anticonvulsant properties of carbamazepine, Carbatrol may reduce the thyroid function as has been reported with other anticonvulsants. Additionally, anti-malarial drugs, such as chloroquine and mefloquine, may antagonize the activity of carbamazepine.

Thus if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of treatment with Carbatrol, it is reasonable to expect that a dose adjustment may be necessary.

Because of its primary CNS effect, caution should be used when Carbatrol is taken with other centrally acting drugs and alcohol.

Stop norethindrone and ethinyl estradiol tablets (chewable) and ferrous fumarate tablets (chewable) if an arterial or deep venous thrombotic (VTE) event occurs. Although the use of COCs increases the risk of venous thromboembolism, pregnancy increases the risk of venous thromboembolism as much or more than the use of COCs. The risk of venous thromboembolism in women using COCs is 3 to 9 per 10,000 woman-years. The excess risk is highest during the first year of use of a COC. Use of COCs also increases the risk of arterial thromboses such as strokes and myocardial infarctions, especially in women with other risk factors for these events. The risk of thromboembolic disease due to oral contraceptives gradually disappears after COC use is discontinued.

If feasible, stop norethindrone and ethinyl estradiol tablets (chewable) and ferrous fumarate tablets (chewable) at least 4 weeks before and through 2 weeks after major surgery or other surgeries known to have an elevated risk of thromboembolism.

Start norethindrone and ethinyl estradiol tablets (chewable) and ferrous fumarate tablets (chewable) no earlier than 4 weeks after delivery, in women who are not breastfeeding. The risk of postpartum thromboembolism decreases after the third postpartum week, whereas the risk of ovulation increases after the third postpartum week.

COCs have been shown to increase both the relative and attributable risks of cerebrovascular events (thrombotic and hemorrhagic strokes), although, in general, the risk is greatest among older (> 35 years of age), hypertensive women who also smoke. COCs also increase the risk for stroke in women with other underlying risk factors.

Oral contraceptives must be used with caution in women with cardiovascular disease risk factors.

Stop norethindrone and ethinyl estradiol tablets (chewable) and ferrous fumarate tablets (chewable) if there is unexplained loss of vision, proptosis, diplopia, papilledema, or retinal vascular lesions. Evaluate for retinal vein thrombosis immediately.

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).